An interview with Philip Vanek, chief commercialization officer of the International Society for Cell & Gene Therapy (ISCT), ...

The recent announcement of RFK Jr.’s termination of mRNA vaccine contracts is the latest effort to undermine this promising ...

In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

After exiting the FDA less than two weeks ago for unclear reasons, Vinay Prasad is once again director of the Center for ...

The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Strand Therapeutics' lead asset is STX-001, an intra-tumor self-replicating mRNA therapy that carries a payload expressing ...

The German giant has already trimmed more than 10,000 employees since initiating a massive restructuring initiative in July ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...